Rhabdomyolysis: a case study exploring the possible side effect of lipid lowering medication by a HIV positive patient taking a protease inhibitor

De Carvalho, Diana; Citro, Mark; Tibbles, Anthony
December 2008
Journal of the Canadian Chiropractic Association;Dec2008, Vol. 52 Issue 4, p243
Academic Journal
This case study explores the incidence of rhabdomyolysis in a HIV positive patient that was taking a lipid lowering drug and a protease inhibitor concurrently while under chiropractic treatment for generalized muscular soreness. Dyslipidemia is a very common problem both in the general and HIV population, with many patients being prescribed lipid lowering drugs. While extremely rare, adverse effects of lipid lowering drugs have been documented to include myopathy such as rhabdomyolysis. It is imperative that chiropractors are aware of the possible adverse side effect of lipid lowering drug therapy in their patients complaining of musculoskeletal pain. It is even more important that chiropractors treating the HIV population are aware of the potential interactions between these medications and protease inhibitors to cause myopathy.


Related Articles

  • Effect of Darunavir on Lipid Profile in HIV-infected Patients. Overton, Edgar Turner; Arathoon, Eduardo; Baraldi, Ezio; Tomaka, Frank // HIV Clinical Trials;Sep/Oct2012, Vol. 13 Issue 5, p256 

    Highly active antiretroviral therapy regimens, consisting of a ritonavir-boosted protease inhibitor (PI) and 2 nucleoside reverse transcriptase inhibitors, are established first-line regimens for HIV-infected patients. However, a common adverse effect in patients receiving Pis is dyslipidemia,...

  • lipodystrophy. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p469 

    An encyclopedia entry for "lipodystrophy" is presented. It refers to a kind of disorders where the metabolism or chemical transformation of fat in the body is changed, resulting to abnormalities in the distribution of fat in the body. An example of lipodystrophy is acquired by people being...

  • The Role of Protease Inhibitor Therapy in Children with HIV Infection. Gavin, P.J.; Yogev, R. // Pediatric Drugs;2002, Vol. 4 Issue 9, p581 

    In comparison with HIV infection in adults, higher HIV RNA levels in children with perinatal HIV infection, differences in the natural history of HIV disease progression, and the presence of a relatively immature immune system contribute to the more complex and problematic nature of pediatric...

  • Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing. Laura Dickinson; Marta Boffito; Saye H. Khoo; Malte Schutz; Leon J. Aarons; Anton L. Pozniak; David J. Back // Journal of Antimicrobial Chemotherapy (JAC);Jul2008, Vol. 62 Issue 1, p161 

    Objectives One potential concern of once-daily protease inhibitor administration is low trough concentrations and ultimately the ‘forgiveness’ or robustness in comparison with the originally licensed twice-daily dose. To give an estimation of ‘forgiveness’, we...

  • Perception of Quality of Life of Persons with HIV/AIDS and Maintenance of Nutritional Parameters While on Protease Inhibitors. Echeverria, Pamela S.; Nonnalagadda, Satya S. // AIDS Patient Care & STDs;Jul99, Vol. 13 Issue 7, p427 

    Investigates quality of life issues biochemical indices and nutritional parameters of individuals with HIV/AIDS before the initiation of protease inhibitors (PI) and after PI therapy. Determination of intake of liquid nutritional supplements, use of micronutrient and herb supplements and...

  • PARONYCHIA WITH PROTEASE INHIBITORS.  // AIDS Patient Care & STDs;Nov99, Vol. 13 Issue 11, p680 

    Reports the development of paronychia on HIV patients who took triple-regimen of protease inhibitors in California. CD4 cell counts of the patients; Link of paronychia to lamivudin; Drugs taken by persons who developed paronychia.

  • SUSTIVA ADDED TO THREE-DRUG COMBINATION.  // AIDS Patient Care & STDs;Oct98, Vol. 12 Issue 10, p803 

    Presents information on a study which used the drug Sustiva in combination with Crixivan, a protease inhibitor and two nucleoside analogues in HIV patients. Analysis of the patients; Reduction in the patients' HIV-RNA; Findings of the study.

  • Virologic Outcome and Predictors of Virologic Failure of Highly Active Antiretroviral Therapy.... Knobel, Hernando; Guelar, Ana; Carmona, Alexia; Espona, Mercedes; Gonzalez, Alicia; Lopez-Colomes, Jose L.; Saballs, Pedro; Gimeno, Juan L.; Diez, Adolfo // AIDS Patient Care & STDs;Apr2001, Vol. 15 Issue 4, p193 

    Reports the causes of the virologic failure of highly active antiretroviral therapy (HAART) in HIV infected individuals in Barcelona, Spain. Role of protease inhibitors in virologic failure; Factors affecting viral load suppression; Predictors of virologic failure.

  • Can AIDS drugs cause sexual dysfunction? Cerrato, Paul L. // RN;May99, Vol. 62 Issue 5, p100 

    Reports on the a study which examined the contribution of protease inhibitors to erectile dysfunction, loss of libido and inability to ejaculate in HIV-infected patients in Spain.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics